Aptevo Q2 2026: $13.1M Loss, Going Concern Warning, and $4.5M Financing
APVO is trading near its 52-week low of $3.35 (4.8% above the low).
Summary
Aptevo reported a $13.1M H1 2026 net loss, reiterated going concern doubts, and disclosed a $4.5M financing with heavy warrant overhang.
Key Events · Earnings and Guidance · APVO
-
Q2 2026 Net Loss of $13.1M
For the six months ended June 30, 2026, Aptevo reported a net loss of $13.1 million, compared to $12.6 million in the prior year period. Cash and cash equivalents fell to $9.8 million from $21.6 million at year-end 2025.
-
Going Concern Warning Reiterated
Management states that substantial doubt exists about the company's ability to continue as a going concern for the one-year period from the issuance date, citing recurring losses and negative cash flows. The company will need to raise additional funds.
-
$4.5M Financing with Heavy Warrant Overhang
On August 12, 2026, Aptevo entered into a private placement and warrant inducement transaction, issuing 861,708 shares and warrants to purchase up to 4,308,540 additional shares at $4.03 per share, for gross proceeds of $4.5 million. This creates significant potential dilution.
-
Nasdaq Delisting Risk
The company faces potential delisting from Nasdaq under the new Market Value Requirement of $5 million, which provides no cure period. As of August 12, 2026, the stock price was $3.50, and the market value of listed securities is near the threshold.
Analysis · APVO · Life Sciences
Aptevo's Q2 2026 10-Q reveals a $13.1 million net loss for the first half of 2026, with cash dwindling to $9.8 million. Management reiterates substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital. The filing also discloses a $4.5 million private placement and warrant inducement completed on August 12, 2026, which introduces significant potential dilution. The stock trades near its 52-week low, and the company faces Nasdaq delisting risk under the new Market Value Requirement.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.3% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.86%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $3.35 to $48.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.